Grant McKenzie

Dr. Grant McKenzie

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2021 in Cancers
Verified
Journal Article
Open access
PDF file
MYMehran Yusuf
Mehran Yusuf
GMGrant McKenzie
Grant McKenzie
ARAbbas Rattani
Abbas Rattani
PTPaul Tennant
Paul Tennant
JBJeffrey Bumpous
Jeffrey Bumpous
NDNeal Dunlap
Neal Dunlap
Merkel cell carcinoma (MCC) is a rare, cutaneous neuroendocrine malignancy with increasing incidence. The skin of the head and neck is a common subsite for MCC with distinctions in management from other anatomic areas. Given the rapid pace of developments regarding MCC pathogenesis (Merkel cell polyoma virus (MCPyV)-positive or virus-negative, cell of origin), diagnosis, staging and treatment, and up to date recommendations are critical for optimizing outcomes. This review aims to summarize currently available literature for MCC of the head and neck. The authors reviewed current literature, including international guidelines regarding MCC pathogenesis, epidemiology, diagnosis, staging, and treatment. Subsequently recommendations were derived including the importance of baseline imaging, MCPyV serology testing, primary site surgery, nodal evaluation, radiotherapy, and the increasing role of immune modulating agents in MCC. MCPyV serology testing is increasingly important with potential distinctions in treatment response and surveillance between virus-positive and virus-negative MCC. Surgical management continues to balance optimizing local control with minimal morbidity. Similarly, radiotherapy continues to have importance in the adjuvant, definitive, and palliative setting for MCC of the head and neck. Immunotherapy has changed the paradigm for advanced MCC, with increasing work focusing on optimizing outcomes for non-responders and high-risk patients, including those with immunosuppression.

1 November 2022 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
GMGrant McKenzie
Grant McKenzie
JGJeremy Gaskins
Jeremy Gaskins
ARAbbas Rattani
Abbas Rattani
AOAlexandria Oliver
Alexandria Oliver
WSWilliam Southall
William Southall
SWShiao Woo
Shiao Woo

19 April 2024 in Brachytherapy
Verified
Journal Article
Closed access
APAndres Portocarrero-Bonifaz
Andres Portocarrero-Bonifaz
SSSalman Syed
Salman Syed
MKMaxwell Kassel
Maxwell Kassel
GMGrant McKenzie
Grant McKenzie
VSVishwa M. Shah
Vishwa M. Shah
SSScott R. Silva
Scott R. Silva

15 October 2022 in Cancers
Verified
Journal Article
Open access
PDF file
ARAbbas Rattani
Abbas Rattani
JGJeremy Gaskins
Jeremy Gaskins
GMGrant McKenzie
Grant McKenzie
VSVirginia Kate Scharf
Virginia Kate Scharf
KBKristy Broman
Kristy Broman
MYMehran Yusuf
Mehran Yusuf
Merkel Cell Carcinoma (MCC) is a rare cancer most commonly affecting White patients; less is known for Black patients. We aim to report presentation, treatment, and quality of registry data by race with a secondary endpoint of overall survival. We conducted a retrospective cohort analysis between 2006–2017 via the National Cancer Database of Black and White MCC patients with and without known staging information. Multivariable logistic, proportional odds logistic, and baseline category logistic regression models were used for our primary endpoint. Multivariable Cox regression was used to interrogate overall survival. Multiple imputation was used to mitigate missing data bias. 34,503 patients with MCC were included (2566 Black patients). Black patients were younger (median age 52 vs. 72, p < 0.0001), had higher rates of immunosuppression (28% vs. 14%, p = 0.0062), and were more likely to be diagnosed at a higher stage (proportional OR = 1.41, 95% CI 1.25–1.59). No differences were noted by race across receipt of definitive resection (DR), though Black patients did have longer time from diagnosis to DR. Black patients were less likely to receive adjuvant radiation. Black patients were more likely to have missing cancer stage (OR = 1.69, CI 1.52–1.88). Black patients had decreased adjusted risk of mortality (HR 0.73, 0.65–0.81). Given the importance of registry analyses for rare cancers, efforts are needed to ensure complete data coding. Paramount to ensuring equitable access to optimal care for all is the recognition that MCC can occur in Black patients.

1 March 2024 in Applied Radiation Oncology
Verified
Journal Article
Closed access
GMGrant McKenzie
Grant McKenzie
MKMaxwell Kassel
Maxwell Kassel
ABAndres Portocarrero Bonifaz
Andres Portocarrero Bonifaz
AWAndrew Willett
Andrew Willett
CSChristine Swanson
Christine Swanson
NDNeal Dunlap
Neal Dunlap
Objective: Stereotactic body radiation therapy (SBRT) treatment is an emerging salvage modality for treating oligometastatic malignant lesions within the retroperitoneum. Appropriate planning target volume (PTV) margins are essential when delivering SBRT to effectively cover the target volume. Spine tracking uses bony spinal anatomy for localization during treatment delivery on robotic linear accelerator platforms. The aim of this study is to quantify the PTV margin needed when spine tracking is used for intrafraction motion tracking when treating retroperitoneal metastatic lesions with robotic SBRT. Materials and Methods: A single-institution chart review identified 16 patients with retroperitoneal tumors treated with SBRT over 19 courses in 103 fractions. Daily cone-beam CT images registered based on tumor positioning at the time of treatment were analyzed. Van Herk’s margin recipe was used to calculate the additional PTV margin required if spine tracking was used instead of daily tumor imaging. Patients’ tumors were stratified based on PTV proximity to the vertebral column (≤ 1 cm vs > 1 cm) and location within the retroperitoneum (superior vs inferior to renal artery), with descriptive statistics used to compare the differences of shifts based on location. Results: The additional margins calculated by Van Herk’s margin recipe to adequately cover the PTV within the 95% isodose surface for 90% of the entire patient cohort in the vertical, longitudinal, and lateral directions were 2.7, 2.8, and 2.8 mm, respectively. When tumors were stratified by proximity to the vertebral column, average longitudinal (P < .001) and total shifts (P < .001) were statistically significant. Conclusion: When treating retroperitoneal tumors with robotic SBRT, a minimum isometric margin expansion of 5 mm when creating the PTV is recommended if spine tracking is used for intrafraction motion assessment. Target volumes adjacent to the vertebral column may have PTV margins decreased to 4 mm without compromise in target coverage.

30 November 2024
Verified
Book Chapter
Closed access
PDF file
GMGrant McKenzie
Grant McKenzie
AMAbigail McCallum
Abigail McCallum
AMAdrianna Masters
Adrianna Masters
BWBrian Willliams
Brian Willliams